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CSF  total  protein  (TP)  gel  and  membrane  staining  is  linear  and  consistent.
TP  staining  is an effective  loading  control  for  CSF  Western  blots  (WB).
The  TP  loading  control  outperforms  albumin  as  a CSF  WB  loading  control.
The  TP  loading  control  improves  the sensitivity  and  accuracy  of  CSF  WB.
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Background:  Cerebrospinal  ﬂuid  (CSF)  has  been  used  to identify  biomarkers  of  neurological  disease.  CSF
protein biomarkers  identiﬁed  by  high-throughput  methods,  however,  require  further  validation.  While
Western  blotting  (WB)  is  well-suited  to this  task,  the  lack  of a validated  loading  control  for CSF  WB  limits
the  method’s  accuracy.
New method:  We  investigated  the use  of total  protein  (TP)  as  a CSF  WB  loading  control.  Using iodine-based
reversible  membrane  staining,  we determined  the  linear  range  and  consistency  of  the  CSF  TP  signal.  We
then spiked  green  ﬂuorescent  protein  (GFP)  into  CSF  to create  deﬁned  sample-to-sample  differences  in
GFP levels  that  were  measured  by WB  before  and  after  TP  loading  correction.  Levels  of CSF  complement
C3  and  cystatin  C measured  by WB  with  TP  loading  correction  and  ELISA  in  amyotrophic  lateral  sclerosis
and  healthy  control  CSF  samples  were  then  compared.
Results: CSF  WB  with  the  TP loading  control  accurately  detected  deﬁned  differences  in  GFP levels  and
corrected  for  simulated  loading  errors.  Individual  CSF  sample  Western  blot  and  ELISA  measurements
of  complement  C3 and  cystatin  C were  signiﬁcantly  correlated  and  the  methods  showed  a comparable
ability  to  detect  between-groups  differences.
Comparison  with  existing  method:  CSF  TP staining  has  a greater  linear  dynamic  range  and sample-to-
sample  consistency  than  albumin,  a commonly  used  CSF  loading  control.  The  method  accurately  corrects
for  simulated  errors  in loading  and  improves  the  sensitivity  of CSF  WB  compared  to  using no loading
control.
Conclusions:  The  TP  staining  loading  control  improves  the  sensitivity  and  accuracy  of CSF  WB results.
ublis© 2015  The  Authors.  P
. IntroductionWestern blotting (WB) is an antibody-based technique for
he identiﬁcation of protein targets transferred to a membrane
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following separation by polyacrylamide gel electrophoresis (PAGE).
Reﬁnements to the technique, including the use of ﬂuorescently
labeled antibodies (Dubitsky et al., 2002; Gingrich et al., 2000),
imaging with high dynamic range detectors such as CCDs and
photodiode arrays, and the application of morphological image pro-
cessing to gels and blots (Sternberg, 1983; Taylor et al., 2013) allow
multiplexed detection and quantitative measurement of proteins
in biological samples.
These advances make WB  a valuable tool for protein quantiﬁca-
tion and the validation of biomarkers obtained via high-throughput
methods such as mass-spectrometry. While these high-throughput
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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ethods are a sensitive, unbiased means of identifying protein
iomarkers, validation of putative markers by a complementary
echnique is imperative, as inadequate validation can lead to
oor biomarker performance in a clinical setting (Pepe et al.,
001; Barker, 2003; Cummings et al., 2008). The enzyme linked
mmunosorbent assay (ELISA) remains the “gold standard” for
iomarker validation and is one of the most-widely used tech-
iques for this purpose (Kohler and Seitz, 2012; Gao et al., 2005).
requently, however, high-quality ELISA kits for newly deﬁned can-
idate markers are not commercially available and developing and
alidating an ELISA “in-house” is time-consuming, expensive, tech-
ically challenging, and dependent on the availability of at least two
ighly sensitive and speciﬁc antibodies to the protein of interest.
y contrast, PAGE/WB is a simple, relatively inexpensive method
apable of detecting multiple forms of a given protein target, such
s multimeric forms or cleavage products. These advantages, com-
ined with the aforementioned reﬁnements to the sensitivity and
uantitative performance of the method make it a useful approach
or the study of CSF proteins and the initial validation of candidate
rotein biomarkers.
To ensure accurate, reproducible WB results, proper correction
or technical error, normalization, and processing of the data is
ssential. Traditionally, WB  experiments have used expression lev-
ls of so-called “housekeeping genes” as loading controls to correct
or differences in protein concentration or errors in loading. The
ssumption of this method is that the housekeeping genes (often,
eta-actin, beta-tubulin, or GAPDH) are highly expressed at rela-
ively constant levels across cells, tissues, and disease/injury types.
ncreasingly, however, the validity of this assumption in the analy-
is of cultured cells (Greer et al., 2010; Ferguson et al., 2005; Sikand
t al., 2012), tissue types (Ferguson et al., 2005; Eaton et al., 2013;
erez-Perez et al., 2012; Moritz et al., 2014), and disease/injury
tates (Ferguson et al., 2005; Eaton et al., 2013; Perez-Perez et al.,
012; Liu and Xu, 2006; Krzystek-Korpacka et al., 2014) has been
riticized. As none of the above housekeeping proteins are consid-
red secreted proteins, their validity as loading controls for WB  of
iological ﬂuids can likewise be questioned. In place of the house-
eeping proteins, normalization to total protein (TP) has emerged
s a reliable loading control (Taylor et al., 2013; Eaton et al., 2013;
oritz et al., 2014; Welinder and Ekblad, 2011; Zeng et al., 2013;
ilda and Gomes, 2013; Aldridge et al., 2008; Rivero-Gutierrez et al.,
014; Romero-Calvo et al., 2010; Klein et al., 1995). Following PAGE,
P stains can be used directly on the gel or following transfer to
 PVDF or nitrocellulose membrane. In general, these stains are
inear over several orders of magnitude, correlate well with total
rotein levels obtained by the BCA or Bradford assays, accurately
orrect for errors in loading, and are reversible (Taylor et al., 2013;
aton et al., 2013; Moritz et al., 2014; Welinder and Ekblad, 2011;
eng et al., 2013; Gilda and Gomes, 2013; Aldridge et al., 2008;
ivero-Gutierrez et al., 2014; Romero-Calvo et al., 2010; Klein et al.,
995).
The aforementioned methods have been largely applied to WB
xperiments measuring protein levels in cultured cells or tissue
omogenates. Whether they apply equally well to biological ﬂuids
sed for biomarker discovery and validation, which typically have
ndividual protein abundances spanning several orders of magni-
ude and high levels of proteins such as albumin, is unclear. One
iological ﬂuid of particular interest in the study of biomarkers of
eurological disease is cerebrospinal ﬂuid (CSF). CSF is a clear ﬂuid
hat surrounds the brain and spinal cord. It arises from the secretory
pithelium of the choroid plexus in the brain’s 3rd and 4th ventri-
les. A normal, adult human carries approximately 150 ml  of CSF
nd this volume is turned over 3–4 times per day. The protein con-
ent of CSF varies from approximately 0.3–1.3 g/l  and the most
bundant CSF protein is albumin (Conly and Ronald, 1983; Cushing,
914; Zappaterra and Lehtinen, 2012). CSF has been used to deﬁnence Methods 251 (2015) 72–82 73
protein biomarkers for a host of neurological disorders, includ-
ing Alzheimer’s disease (AD) (Rosenmann, 2012), frontotemporal
lobar degeneration (FTLD) (Hu et al., 2013), Parkinson’s disease
(LeWitt, 2012), amyotrophic lateral sclerosis (ALS) (Ranganathan
et al., 2005), multiple sclerosis (Madeddu et al., 2013), various forms
of CNS tumors (Kalinina et al., 2011), and schizophrenia (Schwarz
and Bahn, 2008), among others.
Despite its obvious utility to neurological disease biomarker
research, a validated methodology and loading control for CSF
biomarker validation by PAGE/WB does not exist. Previous studies
using PAGE/WB of CSF samples have used a variety of loading con-
trols, including albumin (Suon et al., 2010), transthyretin (Khwaja
et al., 2006), and transferrin (Light et al., 2012). Others have used no
loading control or equal CSF volume loading (Castaneyra-Ruiz et al.,
2013; Ditzen et al., 2012). A validated loading control for CSF WB
would improve the accuracy of the obtained results. An ideal CSF
loading control should be able to correct for individual differences
in total protein concentration, which can be large when examining
CSF from healthy and diseased individuals. Moreover, because CSF
samples are obtained by invasive lumbar puncture and are often
scarce in quantity, an ideal loading control should also be amenable
to multiplexed PAGE/WB analysis. With these considerations in
mind, we  investigated the utility of TP as a loading control for CSF
WB.  We  ﬁrst deﬁned the linear range of detection for CSF TP by
gel and membrane stain. Subsequently, we used simulated experi-
ments in which the amounts of CSF total protein and spiked green
ﬂuorescent protein (GFP) were varied individually and in tandem
to evaluate total protein loading’s corrective performance. Lastly,
we extend the method to the validation of two candidate biomark-
ers of ALS, cystatin C and complement C3 (C3). Collectively, the
results demonstrate that iodine-based TP membrane staining is a
reliable, reversible loading control that improves the accuracy of
CSF WB.
2. Materials and methods
2.1. CSF samples
Lumbar puncture was used to obtain CSF samples from sub-
jects at the University of Pittsburgh Medical Center (UPMC) upon
informed patient consent. This study was  approved by the UPMC
institutional review board. After collection, samples were spun at
3000 rpm at 4 ◦C for 10 min  to remove any cells or debris. Sam-
ples were then aliquoted in small volumes and stored in low
protein binding polypropylene tubes at −80◦ C within 2 h of col-
lection. Only CSF samples without visible blood were centrifuged
and hemoglobin levels in all ﬁnal CSF samples were measured
by ELISA to eliminate those with evidence of signiﬁcant levels
of hemoglobin (>200 ng/ml), reﬂecting blood contamination (You
et al., 2005; Hong et al., 2010).
The protein concentration of all samples was  measured using
the BCA assay (Thermo Scientiﬁc; Rockford, IL). To minimize inter-
sample variability for the evaluation of total protein staining as
a loading control, we pooled CSF samples for our initial experi-
ments. Eight pooled samples comprised of CSF from healthy, ALS,
and AD subjects were created. The protein content of the pooled
CSF samples ranged from 0.46 g/l  to 0.78 g/l.  To assess the
linearity of CSF total protein, we concentrated selected pooled CSF
samples using Amicon Ultra 3 K cutoff columns (Millipore; Darm-
stadt, Germany) to permit loading higher amounts of total protein
on PAGE mini gels. In some experiments, recombinant, puriﬁed GFP
(Abcam; Cambridge, MA)  was spiked into pooled CSF samples in
nanogram amounts. For experiments measuring levels of the ALS
candidate biomarkers cystatin C and C3, 10 individual healthy and
10 ALS subject samples were used. The protein content of these
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amples ranged from 0.45 g/l  to 1.3 g/l  and a total of 5 g
as loaded per lane for each sample.
.2. PAGE/Electrophoretic Transfer
Prior to PAGE, CSF samples were added to a mixture containing
× LDS sample loading buffer (2% lithium dodecyl sulfate, 10% glyc-
rol, 200 mM Tris; pH 8.4) and DTT (50 mM ﬁnal concentration). The
amples were diluted with PBS to ensure equal loading volumes and
eated at 70 ◦C for 10 min. Samples were run on 4–12% NuPAGE
is-Tris gradient mini gels (Life Technologies; Grand Island, NY)
t 150 V using MOPS buffer (50 mM MOPS, 50 mM Tris, 0.1% SDS,
 mM EDTA; pH 7.7). Following completion of the PAGE run, sam-
les were transferred to Immobilon FL PVDF membrane (Millipore;
armstadt, Germany) using Towbin buffer (192 mM glycine, 25 mM
ris). To optimize the transfer of CSF high and low molecular weight
roteins, we used a ramped overnight transfer strategy, previously
hown to result in improved transfer of diverse molecular weight
rotein mixtures to membranes (Otter et al., 1987). Membranes
ere transferred at a constant 8 V for 6 h, then a constant 16 V for
 h. This ramped approach improved the transfer of CSF proteins as
ompared to common transfer strategies (e.g., 100 V for 1 h, or 20 V
or 12–16 h; data not shown).
.3. Total protein staining
Total protein (TP) staining was performed on PAGE gels and
VDF membranes following transfer. For TP gel staining, gels were
tained with Bio-Safe Coomassie (Bio-Rad; Hercules, CA) overnight
t room temperature. PVDF membranes were stained for 30 min
t 4 ◦C with Blot FastStain (G-Biosciences; St. Louis, MO), a propri-
tary, reversible TP stain for PVDF membranes, according to the
anufacturer’s instructions. Blot FastStain is a reversible total pro-
ein stain based on iodine binding that produces purple bands.
tained gels and membranes were scanned on an Odyssey CLx
mager (Licor; Lincoln, NE) at 169 m resolution. All processed
mages were free of pixel saturation. PVDF membranes were de-
tained in ultrapure water until no bands could be detected at the
ighest intensity setting of the Odyssey CLx imager.
.4. Western blot
PVDF membranes were blotted using the Benchpro automated
estern blot (WB) processing system (Life Technologies; Grand
sland, NY). Membranes were blocked for 1 h in Licor blocking buffer
Licor; Lincoln, NE), incubated in primary antibodies overnight,
ashed with PBS, incubated in secondary antibodies for 1 h, washed
ith PBS, and imaged on the Odyssey Clx. The following primary
ntibodies were used: rabbit-anti-GFP (1:2,000; Life Technologies;
rand Island, NY; RRID: AB 221569), chicken-anti-GFP (1:2,500;
ves Labs; Tigard, OR; RRID: AB 10000240), mouse-anti-albumin
1:5,000; Proteintech Labs; Chicago, IL; RRID: AB 11042320),
abbit-anti-cystatin C (1:2,000; Proteintech Labs; Chicago, IL; RRID:
B 2088058), and chicken-anti-C3 (1:3,000; Encor Biotechnology;
ainesville, FL). Secondary antibodies (1:10,000) were produced in
oat to the species of the primary antibody and were conjugated
ith IRdye ﬂuorophores visible in the 700 and 800 channels of the
Lx imager. Images were acquired on the CLx imager at 169 m
esolution and all processed images were free of pixel saturation..5. ELISA
Sandwich ELISAs were used to quantitate levels of cystatin C and
3. Cystatin C ELISAs (Biovendor; Asheville, NC) were performednce Methods 251 (2015) 72–82
according to the manufacturer’s instructions. C3 ELISAs were per-
formed as previously described (Ganesalingam et al., 2011).
2.6. Image processing and data analysis
All gel and membrane images were processed in ImageJ
(National Institutes of Health; Bethesda, MD). Images were back-
ground subtracted using a rolling ball algorithm (Sternberg,
1983; Ferreira and Rasband, 2012). Relative quantitation was per-
formed to obtain integrated density values according to published
guidelines (Ferreira and Rasband, 2012; Gassmann et al., 2009).
Individual values were relatively scaled to allow membrane to
membrane comparisons by summing all values from a mem-
brane and dividing each individual value by this total (Degasperi
et al., 2014). Quantitative protein measurements from ELISAs were
obtained by ﬁtting a linear equation to the standard curve and
using this equation to calculate unknown values. Between-groups
comparisons were made using the independent samples T-test
with Sidak correction for multiple comparisons (Sidák, 1967). Cor-
relation between values obtained by ELISA and WB were made
by Pearson correlation. Data were analyzed using Excel 2010
(Microsoft; Tacoma, WA). Final ﬁgures were constructed in Illus-
trator CS5 (Adobe Systems; Mountainview, CA).
3. Results
3.1. CSF total protein staining signal is linear and consistent by
gel or membrane stain
To characterize the CSF total protein (TP) stain signal, we ﬁrst
determined the signal linearity, detection limit, and saturation
limit of CSF TP by gel and membrane stain. These signals were
compared to that obtained by Western blot (WB) for albumin, a
previously used loading control for CSF WB (Suon et al., 2010) and
the most abundant CSF protein. The results of these experiments are
shown in Fig. 1. The CSF TP staining signal is linear (R2 > 0.99) from
0.25 g of total CSF protein to 20 g by Coomassie gel stain and
from 0.25 g to 16 g for PVDF membrane stain. By contrast, sev-
eral points in total protein-albumin WB  signal relationship showed
clear departures from linearity (R2 = 0.97), and a higher degree of
error. Following statistical analysis of the untransformed data, we
used a square root transformation of values along both axes to visu-
alize all points on the graphs in Fig. 1A–C clearly. For comparison,
the range of 0.25–20 g is shown with the untransformed values
for the three methods (Fig. 1D). The detection limits (approximately
10 and 35 ng for gel and membrane stain, respectively) and satu-
ration range (between 40 and 50 g total protein for both) of each
method are shown in Supplemental Fig. 1.
We also evaluated the sample to sample consistency of the CSF
TP signal by loading identical protein amounts from each of our
eight pooled CSF samples. The results of quadruplicate experiments
are shown in Fig. 2. The coefﬁcient of variation (CV; calculated as
[standard deviation/mean]100) was used as a measure of consis-
tency. By gel and membrane stain, CSF TP signal shows a low degree
of variability, with a CV of approximately 5% by either method. The
consistency of the albumin signal by WB was considerably lower,
with a CV of 15.08%. This result was consistent with the data of
Fig. 1, where TP by gel or membrane stain showed a low degree of
error, even when loading large amounts of protein (compare error
bars in Fig. 1D).
3.2. CSF total protein is an effective loading controlTo evaluate the performance of CSF TP staining as a loading con-
trol, we  performed simulated experiments in which CSF TP and
spiked-in GFP were varied in tandem and then individually. Because
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Fig. 1. CSF Total Protein (TP) Linearity. (A) Left, Representative Coomassie stained gel of a serial dilution of increasing amounts of CSF TP ranging from 0.25 g to 40 g from
the  same sample. Right, quantiﬁcation of the TP signal. Square root transformed TP amount (x axis) and sum total normalized, square root transformed integrated density
(y  axis) are plotted in a line-connected XY scatter graph. Data are shown as the mean ± SD for triplicate experiments using separate pooled samples. (B) Same as (A), but
for  PVDF membrane stain. (C) Same as (A and B), but for albumin Western blot. (D) Comparison of the untransformed values obtained by each method over the range of
0.25–20  g total protein loading. Data are shown as the mean ± SD for triplicate experiments using separate pooled samples.
76 M.A. Collins et al. / Journal of Neuroscie
Fig. 2. CSF Total Protein Consistency. The consistency of the CSF total protein signal
was  evaluated by loading 5 g of CSF total protein from eight separate pooled sam-
ples and measuring the resultant integrated density. (A) Representative Coomassie
stained gel. (B) Same as (A), but for PVDF membrane stain. (C) Same as (A and B), but
for albumin WB.  (D) Summary of results. The CV ([standard deviation/mean]100) of
quadruplicate experiments was  determined.nce Methods 251 (2015) 72–82
GFP is not found in human CSF, we  could control the amount of the
protein present in our pooled samples and the sample-to-sample
differences in TP and GFP. We  compared our measurements of indi-
vidual sample TP and GFP levels to the deﬁned, “true” values as
an evaluation of the performance of TP loading correction. As gel
and PVDF membrane total protein staining performed compara-
bly (Fig. 1D), results from GFP spiking experiments are shown only
with the PVDF membrane stain as a loading control. This allowed
for reversible detection of total protein, multiplexed blotting using
two anti-GFP antibodies, and accounts for variability introduced by
the electrophoretic transfer process.
The results of these experiments are presented in Fig. 3. For the
ﬁrst experiment, we  simulated extreme error in loading by vary-
ing the amount of CSF TP and GFP in tandem. In this experiment
the ratio of GFP to total protein was constant across an eight fold
change in TP and GFP (1.25–10 g total protein; 25–200 ng GFP;
Fig. 3A). The TP and GFP signal was  linear across this range of values
(R2 > 0.99 for both). Correction with an ideal loading control in this
example should produce identical values for all samples when the
data are normalized by sum total. As shown in Fig. 3A, correction
by TP signal is able to correct for the loading error (m = 0.0002 in
the y = mx + b equation, where m expected = 0) and produced rel-
atively consistent values (range = 0.19–0.22 for the expected 0.2
corrected value). The corrective performance is inversely related
to the amount of TP, with the worst performance occurring at the
highest amount of TP.
In the second simulation experiment, we varied the amount of
TP (2.5–10 g), but kept the amount of GFP constant (100 ng). This
experiment simulates a WB experiment where different concentra-
tions of a protein are found across samples. Loading by total protein
followed by correction with an appropriate loading control should,
therefore, lead to observable differences in measured values across
samples. As shown in Fig. 3B, TP loading correction results in val-
ues that approximate the true observed differences. By contrast, the
uncorrected values are similar (range = 0.24–0.27 for the expected
uncorrected value of 0.25). We  observed declining performance of
the loading control at the upper range of TP, consistent with the
previous experiment.
For the ﬁnal simulation experiment, we loaded constant
amounts of TP (5 g; CSF TP plus GFP) and created a two-fold dif-
ference in GFP across samples (100–200 ng). Fig. 3C shows that the
uncorrected values obtained from this experiment underestimate
the true fold difference (1.64, 36% error). TP loading correction,
however, allows more accurate determination of fold differences
across samples (1.93, 7% error). Collectively, these experiments
show that CSF TP can correct for errors in loading and permits
accurate detection of true differences in protein abundance.
3.3. Application to the study of candidate ALS CSF biomarkers
In the ﬁnal phase of this study, we compared the performance
of WB  and TP staining to ELISA in the measurement of levels of
two candidate ALS biomarkers, complement C3 (C3) and cystatin
C (Ganesalingam et al., 2011; Goldknopf et al., 2006; Wilson et al.,
2010; Tsuji-Akimoto et al., 2009; Ranganathan et al., 2005), in CSF
from ﬁve ALS and ﬁve healthy control subjects for each protein.
To permit comparisons across blots and platforms, we ﬁrst multi-
plied the concentration of C3 or cystatin C obtained by ELISA by the
volume of CSF loaded for each sample (5 g TP) to generate “true”
values for each subject. Next, these values and obtained WB  val-
ues were normalized by sum total normalization (Degasperi et al.,
2014). To do so, all values for a given blot or ELISA were summed
and each data point divided by this value. This scales all values from
0–1, with the number corresponding to each data point’s propor-
tion of the total signal. The resultant values were used to compare
individual CSF sample measurements and relative between-groups
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Fig. 3. Corrective Performance of CSF Total Protein (TP) Loading Control. (A) Left, Representative images of in-tandem varying spiked GFP and CSF TP. Right, quantiﬁcation
of  the corrected (red squares) and uncorrected (green triangles) normalized integrated density values obtained for each band. (B) Left, representative images of a serially
diluted  CSF TP stained membrane and equal loading GFP WB are shown. Right, quantiﬁcation of the resultant uncorrected and corrected normalized integrated density values
against the true value based on GFP concentration. (C) Left, representative images of a constant TP stained membrane and two-fold difference loaded GFP WB are shown.
Right,  the resultant fold-difference obtained from the uncorrected and corrected values is plotted against the true two-fold difference for triplicate experiments. Plots in (A)
and  (B) represent the mean ± SD of triplicate experiments. (For interpretation of the reference to color in this ﬁgure legend, the reader is referred to the web  version of this
article.)
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Table  1
Summary of Complement C3 and Cystatin C data. A summary of group data obtained by ELISA and WB is shown. ELISA/WB Proportion = the mean indicated group proportion
of  the total signal, p ELISA/WB = the Sidak-corrected, independent samples t-test p value for the between-groups healthy control-ALS comparison, % WB  error = the average
percentage error for the WB-ELISA comparison of each sample, ELISA-WB r = the Pearson correlation coefﬁcient of the ELISA-WB values obtained for each sample, TPLC = total
protein loading control corrected value, No TPLC = value obtained with no total protein loading control correction, p r = the p value of the correlation coefﬁcient indicated in
the  ELISA-WB r column.
ELISA proportion WB proportion p ELISA p WB % WB  error ELISA-WB r p r
Complement C3 Control ALS Control ALS TPLC TPLC
Total  C3 0.0751 0.125 0.0772 0.123 0.03 0.01 14.39 0.9 > 0.001
C3  n/a n/a 0.0827 0.117 n/a 0.07 No TPLC No TPLC
C3 n/a  n/a 0.0405 0.159 n/a 0.028 0.673 0.0329
Total  protein 0.1 0.1 0.109 0.0903 0 0.13
ELISA proportion WB proportion p ELISA p WB  % WB error ELISA-WB r p r
Cystatin C Control ALS Control ALS TPLC TPLC
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uTotal  cystatin C 0.134 0.659 0.118 0.0817 
Total  protein 0.1 0.1 0.0982 0.101 
ifferences of total protein, C3, and cystatin C obtained by each
ethod.
For C3, we performed WB in triplicate and ELISAs in quadrupli-
ate for ﬁve ALS and ﬁve healthy control CSF samples. The results
f these experiments are shown in Fig. 4A–D. Using TP staining
f the PVDF membrane, we did not detect signiﬁcant differences
etween-groups (p = 0.13; Fig. 4A and D). By WB  corrected by TP
oading and ELISA, we detected a signiﬁcant increase in total C3
evels in the CSF of ALS patients compared to controls (p = 0.01 by
B;  p = 0.03 by ELISA; Fig. 4B and D). We  then assessed the corre-
ation of the ELISA and WB results on a sample to sample basis. In
eneral, there was a high degree of agreement between the two
ethodologies (Pearson r = 0.90; average error = 14.39%; Fig. 4C)
nd the total protein corrected values showed a greater degree of
orrelation than the uncorrected values (r = 0.90 and 0.673, respec-
ively; Table 1). C3 is extensively proteolytically cleaved to generate
ragments with cell signaling functions. Electrophoretic separation
ia PAGE permits examination of the individual C3 fragments, in
ddition to total C3 levels. Using this information, we also found
hat levels of C3 were not signiﬁcantly different between-groups
p = 0.07), while levels of C3 were statistically signiﬁcant between-
roups (p = 0.028; Fig. 4B and D).
Cystatin C ELISAs and WBs  were performed in quadruplicate for
 second set of ﬁve ALS and ﬁve healthy control CSF samples. These
esults are shown in Fig. 4E–H. By PVDF membrane stain, we  did not
etect signiﬁcant differences in TP signal between-groups (p = 0.79;
ig. 4E and H). A signiﬁcant decrease in cystatin C was, however,
bserved in the ALS group compared to the control group by ELISA
p = .013) and TP corrected WB  (p = 0.038; Fig. 4F and H). While the
greement between platforms was not as strong as that obtained
or C3, we still observed signiﬁcant correspondence between the
wo methods (Pearson r = 0.654, p = 0.040); average error = 31.24%).
s with C3, correction of the WB signal by total protein staining
mproved the correlation of WB and ELISA results (rcorrected = 0.654,
uncorrected = 0.507; Table 1). Removing ALS sample 2, which had
nexpectedly high WB  signal and error (161%) reduces the over-
ll average error to 15.06% (Fig. 4G). The data from these and the
3 experiments are summarized in Table 1.
. Discussion
Total protein (TP) staining has emerged as a reliable and accu-
ate loading control for Western blots (WB) of cell and tissue
ysates (Taylor et al., 2013; Eaton et al., 2013; Moritz et al., 2014;
elinder and Ekblad, 2011; Zeng et al., 2013; Gilda and Gomes,
013; Aldridge et al., 2008; Rivero-Gutierrez et al., 2014; Romero-
alvo et al., 2010; Klein et al., 1995). Whether it is similarly
seful for the blotting of cerebrospinal ﬂuid (CSF) has not been0.013 0.038 31.24 0.654 0.04
0 0.79 No TPLC No TPLC
0.507 0.134
investigated. Moreover, while a variety of CSF WB loading controls
have been used previously (Suon et al., 2010; Khwaja et al., 2006;
Light et al., 2012; Castaneyra-Ruiz et al., 2013; Ditzen et al., 2012),
their linearity, consistency, and corrective performance have not
been evaluated directly. Here, we  deﬁne the linearity and consis-
tency of CSF TP gel and membrane staining, assess its corrective
performance as a loading control in simulated experiments, and
compare its performance to results obtained by ELISA for the vali-
dation of two candidate ALS biomarkers.
Previous studies have demonstrated an extensive linear range
of TP staining, often spanning several orders of magnitude, using
a variety of reagents (Taylor et al., 2013; Eaton et al., 2013; Moritz
et al., 2014; Welinder and Ekblad, 2011; Zeng et al., 2013; Gilda and
Gomes, 2013; Aldridge et al., 2008; Rivero-Gutierrez et al., 2014;
Romero-Calvo et al., 2010; Klein et al., 1995). In the present study,
we observe a lower saturation range (between 40–50 g; Fig. S1)
and upper limit to the linear range (16 g by PVDF membrane stain
and up to 20 g by Coomassie gel stain versus between 4–8 g by
albumin; Fig. 1D). This result is not surprising, however, as albu-
min  is estimated to comprise at least 60% of the protein content of
CSF (Roche et al., 2008; Wong et al., 2000). Thus, saturation of the
albumin signal occurs rapidly, limiting the overall linearity of the
CSF TP signal. Nevertheless, it should be noted that the linear range
we observe extends from volumes of less than 1 l of CSF to the
maximum permissible on a mini-gel for typical CSF TP concentra-
tions by either PVDF membrane or gel stain. Staining a duplicated
Coomassie gel has been suggested as a corrective control for West-
ern blots previously (Eaton et al., 2013) and we  demonstrate the
larger dynamic range of this method relative to PVDF membrane
staining, consistent with prior reports (Taylor et al., 2013). We,
however, recommend using the membrane stain as a loading con-
trol. Membrane staining accounts for inconsistencies and loss of
protein caused by the transfer of proteins from the gel to the mem-
brane. Moreover, using a reversible membrane stain obviates the
need to run a duplicate gel.
The sample to sample consistency is also an important con-
sideration when choosing a loading control for WB.  Using pooled
samples, we found that the consistency of CSF TP signal by gel or
membrane stain was high (approximately 5% CV by either method;
Fig. 2D). Likewise, we  observed very low variability from gel to gel
by either method while assessing the linearity of CSF TP (Fig. 1A and
B). By contrast, the TP staining pattern for our individual ALS and
healthy control samples was more variable (Fig. 4A and E). Sev-
eral factors could account for this. First, our pooled CSF samples
were largely homogenous in terms of their TP content, spanning
less than a two-fold range, unlike the individual ALS and healthy
control samples, which spanned a three-fold range. Thus, technical
errors and instrument imprecision would be expected to produce
M.A. Collins et al. / Journal of Neuroscience Methods 251 (2015) 72–82 79
Fig. 4. Application of Total Protein (TP) Loading Correction to Candidate ALS CSF Biomarkers. (A) Representative TP stained membrane of 5 g total loading for ﬁve healthy
control  and ﬁve ALS CSF samples. (B) Representative WB  of complement C3 in the CSF of above healthy control and ALS CSF samples. (C) Plot comparing normalized, relative
individual subject C3 levels obtained by ELISA and TP corrected WB  from the above CSF samples. (D) Plot comparing normalized, relative between-groups differences for TP,
C3,  C3, total C3 WB,  and total C3 ELISA. * = corrected p < 0.05. (E–H) Same as (A–D), respectively, but for cystatin C in a second set of ﬁve ALS and ﬁve healthy control CSF
samples. Plots A–D represent the mean ± SD of triplicate WB experiments, E–H quadruplicate WB experiments, and all plots show quadruplicate ELISA results.
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arger variability in our individual samples as compared to the
ooled samples. Second, our individual samples comprised ALS
nd healthy control subjects. Large differences in protein content
including albumin levels) between disease and control CSF sam-
les are well documented (Zappaterra and Lehtinen, 2012; Katila
nd Lappalainen, 1960; Papadopoulos et al., 1959; Lush et al., 1951;
oberts-Thomson et al., 1976). These differences are likely aver-
ged out in the pooled samples, which comprise ALS, AD, and
ealthy control subjects. Importantly then, the results from our
ooled samples likely reﬂect the true consistency of the method,
s they are relatively unaffected by pre-analytical factors.
While albumin is the most abundant protein in CSF by several
rders of magnitude, and thus a likely candidate for use as a loading
ontrol (Suon et al., 2010), we provide several compelling reasons
o avoid using it for this purpose in CSF WB.  First, by WB,  the
inear range and consistency of albumin is considerably less than
hat observed for CSF TP gel or membrane stain (Figs. 1 and 2).
his is likely due to saturating amounts of albumin on the sur-
ace of the membrane, resulting in a signal that is not reﬂective
f the true protein content. In addition, using a TP stained gel or
eversible membrane stain allows the user to analyze total protein
nd then examine multiple individual protein targets on the same
embrane. This is a relevant consideration given that CSF sam-
le volumes are often limited due to the nature of the collection
rocedure. CSF albumin levels have also been shown to change in
esponse to various diseases (Ghasemzadeh et al., 2008; Li et al.,
006; Sidor et al., 2005; Davidsson et al., 2002), making its utility
s a loading control questionable. Lastly, while the albumin band
lone can be used for normalization following gel or membrane TP
taining, its corrective performance and linear range is less than
hat of the TP signal collectively (data not shown).
The corrective performance of a loading control is a consid-
ration of equal importance to its linearity and consistency. We
valuated the corrective performance of CSF TP as a loading con-
rol using simulated experiments in which known amounts of GFP
ere spiked into CSF. The amount of GFP and CSF TP were var-
ed, ﬁrst in tandem, and then separately (Fig. 3A–C, respectively).
he results of these experiments indicate that the CSF TP loading
ontrol is capable of correcting for large errors in sample loading
Fig. 3A) and permits accurate detection of true differences in pro-
ein concentration and abundance (Fig. 3B and C). The corrective
erformance of the total protein loading control began to deterio-
ate at the highest levels of CSF total protein (10 g). Nevertheless,
he range of corrective ability (eight fold; Fig. 3A) vastly exceeds
hat would be expected by individual sample variability, technical
rror, or instrument variability when loading by TP amount or CSF
olume.
After testing the ability of the TP stain to correct for errors in
imulated experiments, we extended the approach to the study of
andidate CSF biomarkers for ALS by blotting for C3 and cystatin
. Using sum total normalization, we converted values obtained
y WB  and ELISA to their corresponding relative proportions.
hile this results in the loss of quantitative information from the
LISAs, it permits a cross-platform comparison of the ability of
ach method to detect relative differences in protein abundance.
sing the TP loading control, we observed signiﬁcant correlation
etween the normalized ELISA and WB data and comparable sen-
itivity in detecting differences in target protein abundance (Fig. 4;
able 1). Further, we highlight the utility of PAGE-based protein
eparation by showing a signiﬁcant elevation of the C3,  but not
3, fragment in ALS samples relative to controls. The performance
f the TP corrected WB  method was not as high when blotting for
ystatin C, although much of the increased error was a result of
n unexpectedly high value from a single ALS sample. Neverthe-
ess, we still detected a signiﬁcant reduction in cystatin C levels
etween-groups, consistent with previous studies (Wilson et al.,nce Methods 251 (2015) 72–82
2010; Tsuji-Akimoto et al., 2009; Ranganathan et al., 2005). While
ELISA, by virtue of its greater dynamic range, sensitivity, and quan-
titative accuracy, will remain the preferred method for validating
CSF biomarkers, our results demonstrate that WB can be a use-
ful and economical method for the assessment of relative protein
levels in CSF samples.
A variety of total protein stains have been used as loading con-
trols for WB  (Taylor et al., 2013; Eaton et al., 2013; Moritz et al.,
2014; Welinder and Ekblad, 2011; Zeng et al., 2013; Gilda and
Gomes, 2013; Aldridge et al., 2008; Rivero-Gutierrez et al., 2014;
Romero-Calvo et al., 2010; Klein et al., 1995). We  predict that many
of these will be suitable for CSF WB.  The choice of stain will be pred-
icated on study goals and available resources. Given the unique
protein composition of CSF, which is at least 60% albumin (Roche
et al., 2008; Wong et al., 2000) and typically has a total protein
concentration of at least 0.4 g/l,  sensitivity and signal saturation
are unlikely to be primary concerns. For a study seeking to probe
low-abundance proteins in CSF by WB at typical linear detection
levels (nanogram range), a microgram amount of CSF total pro-
tein will almost certainly be required, which is far greater than
the nanogram amount detection limits of the stains characterized
here and elsewhere (Taylor et al., 2013; Eaton et al., 2013; Moritz
et al., 2014; Welinder and Ekblad, 2011; Zeng et al., 2013; Gilda
and Gomes, 2013; Aldridge et al., 2008; Rivero-Gutierrez et al.,
2014; Romero-Calvo et al., 2010; Klein et al., 1995). Likewise, the
saturation limit of the stains characterized here was  only reached
following concentration of CSF samples. Reversibility, conversely,
is an important consideration, especially with human CSF sam-
ples, which are often of limited volume. The iodine-based stain
used for this study was completely reversible within 10 min  using
distilled water washes, providing fast and mild destaining condi-
tions. By contrast destaining is longer and harsher with stains such
as Coomassie and Ponceau, and the more recently characterized
Direct Blue 71 (Zeng et al., 2013). We  observed a greater sensi-
tivity of Coomassie gel staining of CSF total protein than PVDF
membrane staining (Fig. S1). This is likely due to the difﬁculty
of electrophoretically transferring small amounts of CSF to PVDF
membrane, however, as we observe a sensitivity of 2 ng by dot blot
with the iodine-based stain used here (data not shown). This is com-
parable to the sensitivity of epicocconone based stains (Moritz et al.,
2014), which for their reversibility, sensitivity, and linear range
are also useful total protein stains for TP loading control. Trihalo-
based tryptophan ﬂuorescence (stain-free) (Taylor et al., 2013) has
emerged as another promising means of using total protein as a
loading control. The signal is linear over a range comparable to that
observed here, although with lower sensitivity. The main draw-
back of the method appears to be the cost of the required gels
and imaging system. The novel loading control evaluation method
we present (Fig. 3) will allow researchers to determine which total
protein stain works best with their protein of interest, sample and
membrane type, and image acquisition system. The method as pre-
sented could easily be adapted to cell or tissue lysates and GFP
substituted for another protein known not to occur in the sample
tested, if needed.
CSF has proven to be useful for the discovery of neurological
disease biomarkers and basic research on the CNS. As recent efforts
at deﬁning the CSF proteome have illustrated, there is a diverse
array of proteins found in both healthy and diseased CSF (Light
et al., 2012; Guldbrandsen et al., 2014; Schutzer et al., 2010). WB
remains an indispensable technique for the study of protein mass,
modiﬁcations, and relative abundance in the CSF. Recent studies
have emphasized, however, that levels of CSF proteins can be rela-
tively unstable and inﬂuenced by a variety of pre-analytical factors
(Simonsen et al., 2013; Persichetti et al., 2014; Toombs et al., 2013,
2014). These observations and the range of total protein concentra-
tions observed across diseases makes clear the need for a corrective
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oading control for CSF WB.  We  have demonstrated that CSF TP is a
inear, consistent, and accurate loading control well-suited to this
urpose.
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